HAL Allergy Group
HAL Allergy Group is a privately held Dutch biopharmaceutical company founded in 1959 that develops, manufactures, and distributes subcutaneous and sublingual allergen immunotherapies for allergic rhinitis, asthma, venom, and food allergies, marketing products in 16 European countries and serving healthcare professionals and allergy patients.
- Company typePrivate
- Founded1959
- HeadquartersLeiden, Netherlands
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What HAL Allergy Group does
HAL Allergy Group is a privately held Dutch biopharmaceutical company headquartered at the Bio Science Park in Leiden, Netherlands, with 251-500 employees. Founded in 1959 and wholly owned by family-owned Droege Group AG, the company develops, manufactures, and distributes allergen immunotherapies (AIT) for the treatment and prevention of allergic diseases. Itself describes as one of the European top players in allergy immunotherapy, HAL Allergy markets products in 16 countries through direct sales organizations in Germany, Poland, Austria, Italy, and Spain, supplemented by distribution partners elsewhere.
The company's core product portfolio consists of subcutaneous immunotherapy (SCIT) injections and sublingual immunotherapy (SLIT) drops, including the SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml products, alongside allergen diagnostic products for in-vivo diagnosis. The proprietary technology platform centers on modified allergen extracts produced at a GMP-certified facility. The development pipeline includes PM50k (house dust mite SCIT, Phase III completed June 2026 with a 30% reduction in Total Combined Rhinitis Scores versus placebo), peanut and tree nut (cashew, hazelnut, walnut) food allergy immunotherapies, and a ragweed respiratory allergy candidate. HAL Allergy also operates HALIX B.V., a wholly-owned CDMO spun off in 2021 that provides GMP biologics manufacturing for external clients.
Revenue is generated through pharmaceutical product sales of SCIT, SLIT, and diagnostic products, distributed via a field sales force targeting allergists, ENT specialists, dermatologists, pulmonologists, and pediatricians. A March 2026 distribution partnership with Advanz Pharma adds biosimilar commercialization in dermatology, pulmonology, and allergology across Germany and Austria. The company targets two primary persona segments: healthcare professionals who prescribe AIT, and allergy patients seeking disease-modifying rather than symptomatic therapy. HAL Allergy holds first-mover regulatory positioning as the first company to achieve marketing authorizations under Germany's Therapieallergene-Verordnung (TAV).
HAL Allergy Group firmographics
Firmographics- Name
- HAL Allergy Group
- Legal name
- HAL Allergy Holding B.V.
- Website
- https://hal-allergy.com
- Company type
- Private
- Founded year
- 1959
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- HAL Allergy Group is a privately held Dutch biopharmaceutical company founded in 1959 that develops, manufactures, and distributes subcutaneous and sublingual allergen immunotherapies for allergic rhinitis, asthma, venom, and food allergies, marketing products in 16 European countries and serving healthcare professionals and allergy patients.
- Ownership category
- akta.pro rank
HAL Allergy Group industry classification
Industry- Product category
- Allergy Immunotherapy Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)
Keywords
Where HAL Allergy Group is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Offices4 records
Markets served
HAL Allergy Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: HAL Allergy generates revenue through the sale of allergy immunotherapy products (SCIT and SLIT) and diagnostic products for allergic diseases. Products are marketed in 16 countries through direct sales organizations and distribution partners.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
HAL Allergy Group product offering
Product offeringCore offering
HAL Allergy Group develops, produces, and distributes allergen immunotherapies for the treatment and prevention of allergic diseases. Its portfolio includes subcutaneous immunotherapy (SCIT) injections, sublingual immunotherapy (SLIT) drops such as SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml, and allergen diagnostic products. Products are manufactured at a GMP-certified facility in Leiden, Netherlands and marketed in 16 European countries.
Product overview
HAL Allergy Group is a European biopharmaceutical company and one of the top players in allergy immunotherapy, offering a portfolio of allergen immunotherapies for treatment and prevention of allergic diseases. The core product portfolio comprises Subcutaneous Immunotherapy (SCIT) injections and Sublingual Immunotherapy (SLIT) drops including branded products SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml, alongside Diagnostic products for allergy diagnosis. The company operates a GMP-certified manufacturing facility in Leiden, Netherlands and markets products in 16 countries across Europe. The pipeline includes PM50k for house dust mite allergy (Phase III), peanut and tree nut immunotherapy candidates, and ragweed allergy treatments. Supporting services include the myAllergy patient information portal.
Differentiator
Problem solved
Functional benefit
Brands
- myAllergy: Patient information portal (www.allergy.de) helping patients understand and manage allergies in collaboration with allergists.
Products and services
- Subcutaneous Immunotherapy (SCIT) Injection-based allergen immunotherapy treatment administered under the skin for respiratory allergies, venom allergies (wasp and bee stings), and food allergies. Prescribed by allergists, ENT specialists, dermatologists, pulmonologists, and pediatricians.
- Sublingual Immunotherapy (SLIT) Drops or liquid preparations containing allergen extracts in glycerinated phosphate buffer, administered under the tongue for treatment of allergic rhinitis, rhino-conjunctivitis, and other allergic diseases. Prescribed for adult patients.
- SUBLIVAC Birch 40,000 AUN/ml Sublingual immunotherapy drops for treatment of allergic rhinitis and rhino-conjunctivitis in adults caused by birch pollen sensitisation; liquid preparation for sublingual administration containing allergen extracts in glycerinated phosphate buffer.
- SUBLIVAC Trees 40,000 AUN/ml Sublingual immunotherapy drops for treatment of allergic rhinitis and rhino-conjunctivitis in adults caused by tree pollen sensitisation; liquid preparation for sublingual administration containing allergen extracts in glycerinated phosphate buffer.
- Diagnostic Products Allergen diagnostic products for in-vivo allergy diagnosis, supporting the identification of allergic sensitisation in patients.
Quantifiable outcome
- SUBLIVAC Birch 40,000 AUN/ml demonstrated 32% improvement in combined symptom and medication score compared to placebo in Phase III trials
- +1 more outcomes
Companies that use HAL Allergy Group
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
HAL Allergy Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
HAL Allergy Group partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Advanz PharmacoreMulti-year strategic distribution partnership in dermatology, pulmonology and allergology. The partnership combines HAL Allergy's expertise in the allergy sector and strong presence with specialists with Advanz Pharma's international experience in marketing specialized medicines and growing role in the biosimilar segment. Goal is to expand access to modern biosimilar therapies for patients in Germany and Austria.
- HOFFRICHTER GmbHminorBoth companies are part of Droege Group and jointly donated respiratory ventilators worth €350,000 to Ukraine through the #WirtschaftHilft initiative.
- Avalon CounselingminorPartnership to provide telephone counseling ('Prima Linea' initiative) for doctors and medical personnel in regions most affected by coronavirus in Italy during the COVID-19 pandemic.
- HALIX B.V.coreHALIX is a corporate venture and spin-off of HAL Allergy, serving as a Contract Development and Manufacturing Organization (CDMO) for GMP manufacturing of biologics. HAL Allergy and HALIX work together, with HALIX providing contract manufacturing services for biopharmaceutical products.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
HAL Allergy Group competitors and assessment
Company assessmentDirect peers
- ALK-Abelló: Danish-listed global leader in allergy immunotherapy (SCIT, SLIT tablets, diagnostics). Directly competes with HAL Allergy across the same allergen categories, prescriber base, and European geographies, but with materially larger scale and US/Asia presence.
- Stallergenes Greer: France-based allergen immunotherapy specialist offering SCIT, SLIT, and diagnostics. Direct competitor to HAL Allergy in European allergy immunotherapy with overlapping product formats and physician targets.
- Allergy Therapeutics: UK-listed specialty vaccine company developing allergy immunotherapies (Pollinex, VLP-based candidates). Competes with HAL Allergy in subcutaneous and sublingual immunotherapy across European markets and shares a similar mid-cap, R&D-intensive profile.
- Leti Pharma: Spanish allergen immunotherapy manufacturer producing SCIT and SLIT products and diagnostics. Direct competitor to HAL Allergy, particularly strong in Spain and Latin America, with comparable product formats and allergy-clinic focus.
- DBV Technologies: French-listed biotech developing Viaskin epicutaneous patches for food allergy (peanut, milk). Competes with HAL Allergy in the food allergy immunotherapy space and shares the same regulatory and reimbursement challenges.
- Aimmune Therapeutics: US-based food allergy immunotherapy developer (Palforzia peanut OIT), now part of Nestlé Health Science. Direct competitor in peanut allergy immunotherapy where HAL Allergy's pipeline is also advancing.
- ROXALL Medizin: German allergen immunotherapy specialist producing SCIT and SLIT products. Regional direct competitor to HAL Allergy in the German market where HAL Allergy has its TAV-authorized portfolio.
Emerging players
- Biomay: Austrian biotech developing recombinant allergen-based immunotherapies, including for grass and birch pollen. Comparable technology platform and allergen focus to HAL Allergy but at earlier development stage.
- Anergis: Swiss clinical-stage company developing contiguous overlapping peptide-based allergy vaccines (e.g., birch pollen). Adjacent allergen immunotherapy competitor with overlapping birch pollen target to HAL Allergy's SUBLIVAC Birch.
Broad incumbents
- Sanofi (Dupixent franchise): Global pharmaceutical major whose Dupixent (dupilumab) biologic is increasingly used for severe asthma and chronic rhinosinusitis with nasal polyps. Competes indirectly with HAL Allergy's respiratory immunotherapy portfolio by treating overlapping patient populations with a different mechanism.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
HAL Allergy Group social profiles
Digital presenceHAL Allergy Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
HAL Allergy Group leadership team
Management profileNumber of profiles
Profiles11 records
HAL Allergy Group subsidiaries and ownership
Company hierarchySubsidiaries1 record
HAL Allergy Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HAL Allergy Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HAL Allergy Group
What does HAL Allergy Group do?
HAL Allergy Group develops, produces, and distributes allergen immunotherapies for the treatment and prevention of allergic diseases. Its portfolio includes subcutaneous immunotherapy (SCIT) injections, sublingual immunotherapy (SLIT) drops such as SUBLIVAC Birch and SUBLIVAC Trees 40,000 AUN/ml, and allergen diagnostic products. Products are manufactured at a GMP-certified facility in Leiden, Netherlands and marketed in 16 European countries.
Is HAL Allergy Group a public or private company?
HAL Allergy Group is a private company. It is classified as corporate owned and is currently operating.
When was HAL Allergy Group founded?
HAL Allergy Group was founded in 1959. It employs 251 to 500 people.
Where is HAL Allergy Group based?
HAL Allergy Group is headquartered in Leiden, Netherlands, in the Europe region.
How does HAL Allergy Group make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are HAL Allergy Group's main competitors?
Direct peers on record are ALK-Abelló, Stallergenes Greer, Allergy Therapeutics, Leti Pharma, DBV Technologies, Aimmune Therapeutics and ROXALL Medizin. Emerging players are Biomay and Anergis. Sanofi (Dupixent franchise) is listed as a broad incumbent.
Does HAL Allergy Group have an API?
No public API is recorded for HAL Allergy Group.
What industry is HAL Allergy Group in?
HAL Allergy Group's product category is Allergy Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization). Its NAICS code is 325414 and its SIC code is 2836.